OncLive TV

Abhinav Deol, MD, discusses the selection of CAR T-cell therapy for patients with relapsed/refractory multiple myeloma.

Stephanie L. Graff, MD, discusses the evaluation of trastuzumab deruxtecan in patients with HER2-zero metastatic breast cancer in the ongoing, phase 2 DESTINY-Breast06 trial.

Bisiayo Fashemi, PhD, discusses how the addition of entinostat to olaparib could help combat PARP inhibitor-resistance in homologous recombination proficient ovarian cancer, as well as the clinical significance of utilizing mouse organoid models to investigate such strategies.

Catherine John, MD, discusses the antitumor effects of sulindac on the prevention and treatment of obesity-driven models of endometrial cancer.

Brian I. Rini, MD, FASCO, discusses the investigation of immunotherapy following disease progression on previous immunotherapy in patients with relapsed/refractory renal cell carcinoma.

Matthew Brunner, MD, discusses the heterogeneity of relapsed multiple myeloma and the various symptoms that patients could experience.

Joyce A. O’Shaughnessy, MD, discusses real-world data for the use of the phase 2 HER2CLIMB trial regimen of tucatinib plus trastuzumab and capecitabine in HER2-positive breast cancer.

Patrick M. Brunner, MD, discusses how collaboration between dermatologists and oncologists is critical for both accurate diagnosis and the selection of effective treatment approaches for patients with blastic plasmacytoid dendritic cell neoplasm.

Priscilla K. Brastianos, MD, explains the differences between low-grade meningiomas and aggressive high-grade tumors.

David A. Braun, MD, PhD, discusses the rationale for evaluating frontline nivolumab and salvage nivolumab plus ipilimumab in patients with advanced renal cell carcinoma in the phase 2 HCRN GU16-260 trial.

Justin W. Taylor, MD, discusses the evolution of frontline treatment options for patients with blastic plasmacytoid dendritic cell neoplasm, including the integration of tagraxofusp-erzs into the treatment armamentarium in this disease space.

Surbhi Sidana, MD, discusses the unmet needs for patients with relapsed/refractory multiple myeloma who could be candidates for CAR T-cell therapy but have impaired renal function, and how clinical trials for these therapies have excluded this subset of patients.

Mary Anne Fenton, MD, discusses findings from the phase 3 DESTINY-Breast02 trial in patients with HER2-positive metastatic breast cancer.

Aaron J. Franke, MD, MS, discusses treatment options for patients with uncommon EGFR mutations in non–small cell lung cancer.

Micheal Foote, MD, discusses the use of tucatinib plus trastuzumab compared with chemotherapy in the management of HER2-amplified metastatic colorectal cancer.

Mary Anne Fenton, MD, discusses findings from the phase 3 DESTINY-Breast03 trial in patients with metastatic, HER2-positive breast cancer.

Abhinav Deol, MD, discusses the efficacy and durability of CAR T-cell therapies in patients with multiple myeloma.

Jeffery Zonder, MD, discusses the derived benefit that has been derived from talquetamab and cevostamab in patients with relapsed/refractory multiple myeloma.

Christopher W. Ryan, MD, professor of medicine School of Medicine at the Oregon Health & Science University, discusses the evolution of therapeutic treatment approaches across the management treatment landscape of renal cell carcinoma.

Zachary Epstein-Peterson, MD, discusses the use of CAR T-cell therapy in mantle cell lymphoma and highlights questions that remain to be answered within the treatment landscape.

Sarah Goldberg, MD, MPH, discusses potential strategies to overcome osimertinib resistance in EGFR-positive metastatic non–small cell lung cancer.

William M. Sikov, MD, discusses the negative outcome seen with palbociclib in the phase 3 PALOMA-2 trial, and compares this to data on other CDK4/6 inhibitors in the first-line treatment of estrogen receptor–positive, HER2-negative breast cancers.

Tania Jain, MBBS, discusses the use of haploidentical donors in myelofibrosis.

Michael B. Atkins, MD, discusses the rationale for launching the phase 2 HCRN GU16-260 trial in patients with advanced renal cell carcinoma.

John L. Hays, MD, PhD, discusses advances in treating patients with HER2-positive colorectal cancer.

Natalie S. Callander, MD, discusses the significance of the phase 3 ATLAS, phase 2 FORTE, and phase 2 MASTER trials in patients with multiple myeloma.

Andrew Kuykendall, MD, discusses agents currently in development for patients with systemic mastocytosis and how these investigational therapies may fit into the overall treatment paradigm for this disease.

Stephanie L. Graff, MD, discusses data from an exploratory analysis of patients with HER2-positive breast cancer and brain metastases enrolled to the phase 2 HER2CLIMB study, and emphasizes the need for such research efforts to move the needle forward for this population.

Zachary Epstein-Peterson, MD, discusses available treatment approaches for patients with mantle cell lymphoma who are transplant eligible or ineligible.

Andrew Kuykendall, MD, discusses the occurrence and management of adverse effects associated with midostaurin and avapritinib in patients with advanced systemic mastocytosis.